Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

Masafumi Ikeda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4050-2086; OpenAlex author ID A5022537134, A5129925128. Sources: OpenAlex.

Their work

Papers
80 (first author 12, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
201
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 3 papers · 2014: 2 papers · 2015: 6 papers · 2016: 4 papers · 2017: 3 papers · 2018: 6 papers · 2019: 5 papers · 2020: 7 papers · 2021: 6 papers · 2022: 6 papers · 2023: 9 papers · 2024: 6 papers · 2025: 9 papers · 2026: 3 papers

Papers 50 of 80

  1. Branched-chain amino acid catabolism is potentially deficient in pancreatic cancer with high-neural invasion. Co-author DOI 10.1038/s41598-026-47741-x↗
  2. Efficacy and safety of nanoliposomal irinotecan plus 5-fluorouracil and l-leucovorin in rare histological subtypes of pancreatic cancer. Last author DOI 10.1093/jjco/hyag044↗
  3. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  4. Electronic Patient-Reported Outcome Quality of Life Score in Japanese Patients With Pancreatic Cancer on Second-Line Chemotherapy: A Multicenter Observational … Co-author DOI 10.1002/cam4.71161↗
  5. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… First author DOI 10.1007/s00535-024-02186-9↗
  6. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… First author DOI 10.1007/s00535-025-02215-1↗
  7. Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. First author DOI 10.1016/j.ejca.2025.115424↗
  8. Consensus statement on the use of systemic therapies in pancreatic ductal adenocarcinoma in Asia. Last author DOI 10.1016/j.esmogo.2025.100158↗
  9. Depth of response in patients with locally advanced pancreatic cancer treated with first-line chemotherapy: A supplementary analysis of JCOG1407. First author DOI 10.1016/j.pan.2025.02.005↗
  10. Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity sco… Co-author DOI 10.1016/j.pan.2025.08.017↗
  11. NALIRIFOX in Japanese treatment-naïve patients with metastatic pancreatic adenocarcinoma: an open-label, phase II trial design. Co-author DOI 10.1080/14796694.2025.2469467↗
  12. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  13. Covered self-expandable metallic stent placement for tumor bleeding from duodenal invasion in patients with unresectable pancreatic cancer. Last author DOI 10.1002/deo2.361↗
  14. Treatment outcomes of gemcitabine plus nab-paclitaxel in pancreatic cancer patients with malignant ascites. Last author DOI 10.1016/j.pan.2024.03.015↗
  15. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  16. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. Co-author DOI 10.1038/s41416-024-02834-0↗
  17. Identification of a urinary CD276 fragment for detecting resectable pancreatic cancer using a C-terminal proteomics strategy. Co-author DOI 10.1038/s41598-024-65093-2↗
  18. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. Co-author DOI 10.1038/s44276-023-00028-4↗
  19. Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort. Co-author DOI 10.1007/s00535-023-02033-3↗
  20. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  21. Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02189-y↗
  22. Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety… Co-author DOI 10.1093/jjco/hyac177↗
  23. Effect of systemic inflammatory response on induction chemotherapy followed by chemoradiotherapy for locally advanced pancreatic cancer: an exploratory subgrou… Co-author DOI 10.1093/jjco/hyad044↗
  24. Fibroblast inhibition by tocilizumab enabled gemcitabine/nab-paclitaxel rechallenge for pancreatic cancer. First author DOI 10.1111/cas.15929↗
  25. Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Last author DOI 10.1186/s13014-023-02367-5↗
  26. Correction: Palliative radiotherapy for tumor bleeding in patients with unresectable pancreatic cancer: a single-center retrospective study. Last author DOI 10.1186/s13014-023-02377-3↗
  27. Clinical course of anorexia-cachexia according to type of first-line chemotherapy for advanced pancreatic cancer Last author DOI 10.21203/rs.3.rs-3048794/v1↗
  28. Interleukin 6/gp130 axis promotes neural invasion in pancreatic cancer. Co-author DOI 10.1002/cam4.4823↗
  29. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… Co-author DOI 10.1016/j.ejca.2022.06.010↗
  30. Incidence of and risk factors for severe neutropenia during treatment with the modified FOLFIRINOX therapy in patients with advanced pancreatic cancer. Last author DOI 10.1038/s41598-022-18669-9↗
  31. Endoscopic duodenal stent placement versus gastrojejunostomy for unresectable pancreatic cancer patients with duodenal stenosis before introduction of initial … Co-author DOI 10.1093/jjco/hyab194↗
  32. Germline variants in cancer-predisposing genes in pancreatic cancer patients with a family history of cancer. Co-author DOI 10.1093/jjco/hyac110↗
  33. Neoadjuvant S-1 With Concurrent Radiotherapy Followed by Surgery for Borderline Resectable Pancreatic Cancer: A Phase II Open-label Multicenter Prospective Tri… Co-author DOI 10.1097/sla.0000000000004535↗
  34. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study. Last author DOI 10.1007/s00280-020-04206-w↗
  35. A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer. Co-author DOI 10.1007/s10147-021-02001-y↗
  36. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  37. Impact of Renal Function on S-1 + Radiotherapy for Locally Advanced Pancreatic Cancer: An Integrated Analysis of Data From 2 Clinical Trials. Co-author DOI 10.1097/mpa.0000000000001879↗
  38. Clinical and Tumor Characteristics of Patients with High Serum Levels of Growth Differentiation Factor 15 in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers13194842↗
  39. Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. Last author DOI 10.3390/diagnostics11071195↗
  40. The "histological replacement growth pattern" represents aggressive invasive behavior in liver metastasis from pancreatic cancer. Co-author DOI 10.1002/cam4.2954↗
  41. nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients. Co-author DOI 10.1002/cam4.3558↗
  42. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort… Last author DOI 10.1007/s00280-020-04110-3↗
  43. Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovaria… Co-author DOI 10.1007/s10147-020-01721-x↗
  44. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001484↗
  45. Extrapancreatic Nerve Plexus Invasion on Imaging Predicts Poor Survival After Upfront Surgery for Anatomically Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001547↗
  46. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy… Co-author DOI 10.1186/s12885-020-07698-0↗
  47. Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer. Co-author DOI 10.1007/s10637-018-0634-5↗
  48. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE tri… Co-author DOI 10.1016/j.ejca.2018.10.004↗
  49. Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Panc… Co-author DOI 10.2169/internalmedicine.2362-18↗
  50. Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Co-author DOI 10.2169/internalmedicine.2539-18↗

Closest collaborators

The 25 strongest of 201 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junji Furuse · 36 shared papers, 2012–2026 · strength 4.05
  2. Makoto Ueno · 30 shared papers, 2012–2026 · strength 3.92
  3. Shuichi Mitsunaga · 34 shared papers, 2011–2026 · strength 3.85
  4. Takuji Okusaka · 36 shared papers, 2011–2026 · strength 3.35
  5. Hiroshi Imaoka · 20 shared papers, 2019–2026 · strength 3.07
  6. Mitsuhito Sasaki · 17 shared papers, 2019–2026 · strength 2.46
  7. Chigusa Morizane · 21 shared papers, 2011–2025 · strength 2.39
  8. Masato Ozaka · 16 shared papers, 2018–2026 · strength 2.35
  9. Naohiro Okano · 13 shared papers, 2020–2025 · strength 1.86
  10. Satoshi Kobayashi · 12 shared papers, 2020–2026 · strength 1.73
  11. Nobumasa Mizuno · 18 shared papers, 2015–2024 · strength 1.67
  12. Tatsuya Ioka · 18 shared papers, 2013–2026 · strength 1.62
  13. Taro Shibuki · 7 shared papers, 2021–2026 · strength 1.33
  14. Akihiro Ohba · 8 shared papers, 2021–2025 · strength 1.28
  15. Takeshi Terashima · 8 shared papers, 2021–2025 · strength 1.26
  16. Tomoyuki Satake · 6 shared papers, 2023–2026 · strength 1.18
  17. Kumiko Umemoto · 8 shared papers, 2020–2025 · strength 1.08
  18. Hiroshi Ishii · 13 shared papers, 2013–2023 · strength 1.02
  19. Tomonao Taira · 5 shared papers, 2023–2026 · strength 1.00
  20. Kanae Inoue · 5 shared papers, 2023–2026 · strength 1.00
  21. Kunihiro Tsuji · 7 shared papers, 2018–2025 · strength 0.90
  22. Atsushi Ochiai · 11 shared papers, 2012–2023 · strength 0.90
  23. Yasuyuki Kawamoto · 6 shared papers, 2022–2025 · strength 0.90
  24. Masayuki Furukawa · 8 shared papers, 2015–2024 · strength 0.76
  25. Kohei Nakachi · 9 shared papers, 2011–2025 · strength 0.75

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.